MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians

医学 电流(流体) 药物治疗 医学物理学 内科学 工程类 电气工程
作者
Ashish Kumar
出处
期刊:Journal of Association of Physicians of India [Association of Physicians of India]
卷期号:73 (7): e45-e60 被引量:1
标识
DOI:10.59556/japi.73.1058
摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a significant public health issue worldwide, with a pronounced impact in India due to the escalating rates of obesity and type 2 diabetes mellitus (T2DM) driving its prevalence. This condition spans a range of hepatic disorders, from uncomplicated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), accompanied by differing levels of hepatic fibrosis, heightening the likelihood of progression to cirrhosis, liver cancer, and cardiovascular complications. While lifestyle modification remains the cornerstone of MASLD management, pharmacologic therapies are increasingly recognized as essential for patients with progressive disease or those at higher risk of complications. Recent insights into the pathogenesis of MASLD have led to the development of innovative therapies targeting key mechanisms such as hepatic steatosis, insulin resistance, inflammation, and hepatic fibrosis. Several pharmacological agents have shown encouraging results in clinical trials, including thyroid hormone receptor-β agonist resmetirom, glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide, peroxisome proliferator-activated receptor (PPAR) agonists such as pioglitazone and saroglitazar, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and vitamin E. Furthermore, emerging therapies, including the dual incretin agonist tirzepatide and fibroblast growth factor (FGF) analogs, hold the potential to transform future treatment strategies. This review provides a comprehensive overview of current and evolving pharmacologic options for MASLD, with a focus on practical recommendations tailored for Indian physicians. A structured treatment algorithm for noncirrhotic MASLD (F0-F3 fibrosis) is presented, incorporating only drugs currently available in India and stratified based on diabetes status and hepatic fibrosis severity. Given India's vast and diverse patient population, ensuring access to cost-effective therapies remains a challenge, necessitating a pragmatic approach that balances efficacy, affordability, and real-world feasibility. This review serves as a practical clinical guide, equipping physicians with evidence-based recommendations to optimize MASLD management in routine practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Ava的应助被甜蜜的啤酒采纳,获得10
2秒前
yixuanshi发布了新的文献求助10
2秒前
哇owao完成签到,获得积分10
3秒前
3秒前
dolphin完成签到,获得积分10
3秒前
黎建东完成签到,获得积分10
4秒前
Jasper的应助被饺子采纳,获得10
4秒前
李爱国的应助被qiyue采纳,获得10
4秒前
Jun的应助被科研通管家采纳,获得20
4秒前
上官若男的应助被科研通管家采纳,获得10
5秒前
爆米花的应助被科研通管家采纳,获得10
5秒前
大模型的应助被科研通管家采纳,获得10
5秒前
彭于晏的应助被科研通管家采纳,获得10
5秒前
zws的应助被烊烊烊采纳,获得10
5秒前
5秒前
5秒前
充电宝的应助被烊烊烊采纳,获得10
5秒前
我是老大的应助被科研通管家采纳,获得10
5秒前
本色风情发布了新的文献求助10
5秒前
所所的应助被科研通管家采纳,获得10
5秒前
5秒前
李健的应助被科研通管家采纳,获得10
6秒前
赘婿的应助被科研通管家采纳,获得10
6秒前
jase发布了新的文献求助10
6秒前
6秒前
6秒前
星辰大海的应助被科研通管家采纳,获得10
6秒前
CipherSage的应助被科研通管家采纳,获得10
6秒前
嘻嘻哈哈的应助被123采纳,获得10
6秒前
SciGPT的应助被科研通管家采纳,获得10
6秒前
包容的飞丹完成签到,获得积分10
6秒前
漆漆发布了新的文献求助10
6秒前
彭于晏的应助被科研通管家采纳,获得10
7秒前
Akim的应助被无语的长颈鹿采纳,获得10
7秒前
7秒前
深情安青的应助被科研通管家采纳,获得10
7秒前
NexusExplorer的应助被邵将采纳,获得10
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187835
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843558
捐赠科研通 7785715
什么是DOI,文献DOI怎么找? 3435125
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482008